Boehringer Ingelheim and Portage Biotech have provided series A funding to support a Phase 1 clinical trial for the treatment Sentien is developing for acute kidney injury.
US-based biotechnology developer Sentien Biotechnologies secured an undisclosed amount in series A funding on Friday from pharmaceutical company Boehringer Ingelheim and biotechnology firm Portage Biotech.
Boehringer Ingelheim invested through its US investment subsidiary, Boehringer Ingelheim Venture Fund USA (BIVF).
Sentien’s lead product, Sentinel, is a treatment for acute kidney injury, a kidney failure that is sometimes caused by heart surgery. The funding will support a Phase 1 clinical trial for Sentinel.
Sentien received a $3m grant from the US National…
